Developing implantable bioengineered kidney tissue to get end-stage renal disease patients off dialysis without a transplant.
Trestle Biotherapeutics is developing implantable therapeutic tissues as a stem cell-based treatment for end-stage renal disease (ESRD). The implantable bioengineered tissue aims to supplement renal function, eliminate dependency on dialysis, and delay or replace kidney transplantation. The company uses stem cell biology, biofabrication, fluidics, and cell manufacturing, and has a research collaboration with Humacyte and received a $1 million prize from the KidneyX Innovation Accelerator Artificial Kidney Prize. Trestle Biotherapeutics is a product of Trestle Biotherapeutics.